Skip to content

Other, net at other companies

Biodesix, Inc. logo
Biodesix, Inc.BDSX
-$158K+20.2%
Baxter International logo
Baxter InternationalBAX
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Charles River Laboratories logo
Charles River LaboratoriesCRL
Labcorp Holdings logo
Labcorp HoldingsLH
Danaher logo
DanaherDHR

Other financials

Income statement

See full
Revenue$23.2M-36.4%
Gross profit$4.5M-68.1%
Operating income-$4.7M
Net income-$15.0M-1,206%
EPS (diluted)-$0.43-1,333%

Balance sheet

See full
Cash & equivalents$20.8M+152%
Total debt$156.9M+1,310%
Total equity-$28.4M-2,229%
Total assets$225.5M-5.8%

Cash flow

See full
Operating cash flow$4.7M
CapEx$1.1M-46.7%
Free cash flow$3.6M

Valuation

See full
Market cap$196.92M-35.4%
Enterprise value$333.06M+8.3%
P/S1.6×+0.5×

Profitability

See full
Gross margin31.3%-1.4pp
Operating margin-14.5%-2.2pp
Net margin-30%
FCF margin-36.4%

Returns & leverage

See full
Return on equity-612.1%
Debt / equity8.3×-1.5×
Current ratio3.8×+0.9×

Where this comes from

Reported directly by Lifecore Biomedical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromPaymentsForOtherFinancingActivities.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s other, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lifecore Biomedical, Inc.'s other, net?
Lifecore Biomedical, Inc. (LFCR) reported other, net of -$256K in Q1 2026.
What does other, net mean?
Includes miscellaneous cash flows related to financing activities that are not categorized as debt issuance, dividends, or share repurchases. This may include changes in non-controlling interests, debt issuance costs, or other unique financing-related transactions. It provides a comprehensive view of non-standard financing cash movements.